The Role of Combination Therapy in mCRPC
Rashid K. Sayyid, MD, MSc, discusses the role of combination therapy in metastatic castrate-resistant prostate cancer.
Stay updated with breaking news from Radium 223. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Rashid K. Sayyid, MD, MSc, discusses the role of combination therapy in metastatic castrate-resistant prostate cancer.
Expert perspectives on the treatment approach for patients with metastatic castrate-resistant prostate cancer.
A urologic oncology fellow provides a comprehensive overview of systemic therapy options for patients with prostate cancer.
Radium-223 was safe and did not preclude patients with metastatic castration-resistant prostate cancer from receiving subsequent life-prolonging therapies, including chemotherapy.
Drs Armstrong and Manning review the safety and efficacy data from the ALSYMPCA trial of radium-223 in patients with mCRPC.